




Histone 3 Lysine 27 and
can be Reversed by
Valproic Acid Treatment
in Inflammatory Bowel
Disease PatientsBenefits from biologic therapy for in-
flammatory bowel disease (IBD) come
at a cost of side effects and antidrug
antibodies.1 This necessitates novel
anti-inflammatory therapies.
Histone acetylation is an impor-
tant epigenetic gene expression
regulator. Acetylation of histone-3
lysine-27 (H3K27ac), H3K9ac, and
trimethylation of H3K4 (H3K4me3)
mark active enhancers. H3K27ac can
differentiate active from poised en-
hancers and is linked to gene
expression.2 Trimethylation of
H3K27 leads to gene repression.
IBD-associated single-nucleotide
polymorphisms overlap with regula-
tory elements marked by H3K27ac.3
H3K27ac is reduced in dextransulfate sodium (DSS)-induced colitis
in mice and broad-acting histone
deacetylases (HDAC) inhibitors (eg,
SAHA and valproic acid [VPA])
restore H3K27ac levels and inhibit
inflammatory cytokine production.4,5
We extend findings from models to
patients with IBD to evaluate the
therapeutic potential of HDAC in-
hibitors. We assessed H3K27ac in pa-
tients with IBD and tested whether
VPA could inhibit inflammatory cyto-
kine production in IBD biopsies
cultured ex vivo. VPA was selected
because of its safety record in treating
neurologic disorders. Methods and
patient characteristics are given in the
Supplementary Material.
To validate our approach, we
confirmed a reduction in the percent-
age of H3K27ac positive (H3K27acþ)
cells in conjunction with the develop-
ment of inflammation in a DSS model
(Figure 1A–C).4 Moreover, after
removal of DSS, H3K27acþ cells
significantly increased during resolu-
tion of inflammation (Figure 1C). No
significant changes in HDAC mRNA
were detected during the inflammatory
phase, despite an increase in inter-
leukin (IL) 6 mRNA levels (positive











removal. SDuring the resolution of inflammation
(Day 17), expression of 4 Hdacs
differed from baseline (downregulated,
Hdac1, 5, and 10; upregulated, Hdac2)
(Figure 1D).
A reduction in H3K27acþ cells was
confirmed in actively inflamed IBD bi-
opsies relative to inactive IBD control
subjects (Figure 2A and B) and was
maintained in a paired subanalysis of
the same samples between patient
matched active and inactive segments
(-16.25%; P ¼ .0243; n ¼ 11). This
indicated that confounding factors,
including disease duration and medi-
cations, could not account for the
observed differences. A similar pattern
of change was observed in patients
with Crohn’s disease (CD) and ulcer-
ative colitis (UC), although the reduc-
tion in H3K27acþ cells in active
biopsies was significant only in pa-
tients with UC (Figure 2B). As in the
DSS model, active disease in patients
with IBD was marked by increased IL6
mRNA but was not associated with
changes in HDAC mRNA levels
(Figure 2C). A subanalysis of patients
with UC and CD (Supplementary
Figure 1) found increased HDAC 9 in
UC consistent with its inflammatory
role.6A) H3K27ac in mouse DSS colitis.
tive Masson trichrome and H3K27ac
Assessment of trichromatee stains
an increase in inflammation markers
treatment, which lowered on DSS
) Conversely, percentage of H3K27acþ
eased following DSS treatment and
following DSS removal. (D) DSS treat-
iated with increased IL6 mRNA levels.
ot alter HDAC mRNA levels, although
eased during recovery following DSS
ignificant changes: *< .05, **< .01.
Figure 2. (A, B) Fluorescent pro-
tein analysis of the percentage of
H3K27acD cells in inactive and
active patients with IBD
confirmed a reduction in active
relative to inactive IBD control
subjects. (C) No changes in HDAC
mRNA were observed in IBD bi-
opsies with active disease. (D)
Culturing biopsies with an HDAC
inhibitor (5 mM VPA) increased the
percentage H3K27acþ cells in IBD
biopsies relative to patient-
matched biopsies treated with a
vehicle control (RPMI medium), and
(E–G) decreased inflammatory
cytokine mRNA levels and protein
production. Significant changes: *<
.05, **< .01, ***< .001, and ****<
.0001. ELISA, enzyme-linked
immunosorbent assay; IFNG, inter-
feron gamma; NS, not significan;
TNF, tumor necrosis factor.
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IBD biopsies cultured ex vivo with 5
mM VPA (Figure 2D) increased
H3K27ac levels and reduced expres-
sion of IL6, IL10, IL1B, and IL23 mRNA
significantly relative to patient-
matched biopsies treated with control
media (Figure 2E). Reduced produc-
tion of IL6, IL10, and IL23 protein into
culture media was confirmed
(Figure 2F), and a reduction in tumor
necrosis factor and interferon gamma
was found (Figure 2F). Analysis of IL6
in an expanded cohort again indicated
that VPA effects were greater in bi-
opsies from areas with active disease,
and in patients with UC (Figure 2G);
namely, groups that had the most
pronounced reductions in H3K27acþ
cells (Figure 2B).
In biopsy cultures, we cannot
discern the primary cellular source of
IL6 or other inflammatory cytokines.
VPA can suppress inflammation by
inducing apoptosis of laminal propria
mononuclear cells,7 and we observed adecrease in BLC3 mRNA and an in-
crease in CASP9 expression in VPA-
treated IBD biopsies (Supplementary
Figure 2). Although not significant,
there was an increase in the percent-
age of CASPþ cells in VPA-treated
biopsies and the proportion of
CASPþ/CD3þ T cells (Supplementary
Figure 2).
Other potentially relevant mecha-
nisms of action for VPA include modu-
lation of acetylation at inflammatory
gene promoters and regulation of
microRNAs. For example, in a model of
colitis-accelerated colon carcinogenesis,
DSS treatment increased HDAC activity
and decreased H3K27ac levels in the
intestine. However, promoters of in-
flammatory genes, including the IL6
promoter, were hyperacetylated.
Conversely, anti-inflammatory treat-
ment with aspirin increased global
acetylation levels but reduced H3K27ac
levels at the promoter regions of
proinflammatory genes.4 Others have
reported that in T cells, HDAC inhibitorspromote FOXP3 expression by acety-
lating its promoter and inducing
microRNA signatures associated with
regulatory T cells. Thus, reducing IL6/
STAT3/IL17 signaling in naive CD4þ T
cells and blocking the polarization of
Th17 cells.8 HDAC inhibitors also acet-
ylate nonhistone proteins including
STAT1, blocking their phosphorylation
and inhibiting proinflammatory signal-
ling.9 Increasing histone acetylation may
alter other histone modifications (eg,
H3K27me3), which is altered by DSS
treatment.
VPA can have HDAC-independent
effects, including regulating DNA
methylation leading to gene repression
and metabolic changes. Because
chemically diverse HDAC inhibitors
have similar effects, an HDAC-
dependent mechanism seems likely.
Indeed, SAHA (vorinostat), which is
more potent than VPA in IBD models
but currently only used for cutaneous
T-cell lymphoma, is being trailed in
patients with CD.10
2021 Hypoacetylation and Valproic Acid in IBD 891Our data identify H3K27ac levels in
the mucosa as a potential biomarker of
response to HDAC therapy and estab-
lish ex vivo biopsy cultures as an
alternative screen for HDAC inhibitors.
Although further work is needed to
elucidate VPA mechanism of action, we
highlight the potential to repurpose
VPA, a widely used and inexpensive
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Supplementary Material
Materials and Methods
Dextran Sulphate Sodium Exposed
Mice. Animal experiments were
approved by the Ethics Committee for
Animal Experimentation of the Fon-
dazione IRCCS Istituto Nazionale dei
Tumori of Milan. C57BL/6 wild-type
mice (4–6 weeks) were purchased
from Charles River and housed in
filter-top cages held under pathogen-
free conditions. Mice were adminis-
tered 1.5% DSS in drinking water for
10 days. Recovery was evaluated 10
days after DSS withdrawal. Mice were
sacrificed at Day 0 (n ¼ 3), Day 3 (n ¼
4), Day 10 (n ¼ 4), Day 17 (n ¼ 3), and
Day 22 (n ¼ 3). The colon was
removed, washed in phosphate-
buffered saline (PBS) and formalin
fixed and paraffin embedded (FFPE).
Other mice were sacrificed at Day
0 (n ¼ 3), Day 10 (n ¼ 3), and Day 17
(n ¼ 3) and the colon homogenized in
Trizol reagent (Invitrogen, Waltham,
MA) before RNA extraction.
Robarts histopathology index score
of trichromatin-stained FFPE sections
monitored disease activity.1 The
Robarts histopathology index score
correlated well with previously pub-
lished measures in these mice.2,3
Immunohistochemistry for
Mouse Formalin Fixed and
Paraffin Embedded Tissue
H3K27acþ nuclei were quantified us-
ing standard immunohistochemistry
protocols. Antigen retrieval was per-
formed in citrate buffer pH 6.0 for 20
minutes in a microwave. Slides were
cooled in a 1x PBS solution for 2 mi-
nutes, before blocking in goat serum
for 15 minutes (Dake, diluted 1:25).
Primary anti-H3K27ac (ab4729,
Abcam, Cambridge, MA; 1:1000) was
added and incubated for 45 minutes at
room temperature, followed by a PBS
wash (5 minutes under agitation). The
secondary antibody (goat antirabbit
horseradish peroxidase secondary
antibody, 1:250; Dako) was added and
incubated for 45 minutes. Next, slides
were washed in 1x PBS, before incu-
bation with 3,3’-dianminobenzidine
solution for 10 minutes, washed in
distilled water and counterstained
with hematoxylin. Finally, slides were
dehydrated and mounted from xylene
using distyrene plasticizer reagent. All
slides were scanned using the Nano-
Zoomer Digital Pathology (NDP.view2)
system (Hamamatsu Corp, Bridge-
water, NJ).
For H3K27ac quantification 3 high-
power fields of the mucosa were taken
from each slide, processed on ImageJ,
and each field counted to assess posi-
tively stained (brown) and total nuclei
(brown and purple). H3K27acþ cells
were expressed as a percentage of the
total number of cells. Between 600
and 1800 nuclei were analyzed per
field.
Immunofluorescence
Surgically resected intestinal FFPE
tissue sections from patients with IBD
were obtained from the Royal London
Hospital Pathology Archive. Specimens
with dysplasia or established malig-
nancy were excluded. IBD FFPE tis-
sues analyzed (n ¼ 28) included 11
inactive IBD samples (CD, n ¼ 8; UC,
n ¼ 3) and 17 active IBD samples (CD,
n ¼ 9; UC, n ¼ 8). The cohort included
11 inactive and active patient matched
pairs. Disease activity for each block
was assessed using pathology reports.
Cohort characteristics are shown in
Supplementary Table 1.
For H3K27ac analysis antigen
retrieval and primary antibody in-
cubations were performed as
described in the immunohistochem-
istry section. However, H3K27ac
staining was visualized using a fluo-
rescent secondary antibody
(Ab150077, diluted 1:250 in PBS), and
Vectashield HardSet (Vector Bio-
systems, Malvern, PA) mounting me-
dium with DAPI was used for
counterstaining. Imaging used 40
magnification. H3K27acþ nuclei were
scored manually from 3 independent
mucosal images. H3K27acþ nuclei
were expressed as a percentage of the
total number of cells in that field.
Typically, 200–400 nuclei were scored
per field. Data were normally distrib-
uted and differences in the percentage
of H3K27acþ cells between active and
inactive IBD tissue determined using a
2-tailed Student t test assuming equal
variance. A subanalysis of the paired
patient-matched inactive and active




IBD biopsies from the same area of the
intestine were collected during routine
endoscopies at the Royal London
Hospital. For each patient the disease
activity, age, date of diagnosis, exten-
sion and behavior of disease (Montreal
classification), clinical activity of dis-
ease (Harvey-Bradshaw Index for CD
and Mayo score for UC), comorbidities,
and all previous and current medica-
tions were recorded. Exclusion criteria
included a diagnosis of infective colitis
and prior use of VPA. In total 29 pa-
tients with IBD were recruited, but not
all patients had sufficient biopsies
taken to be included in all analyses.
The numbers for each analysis are
listed individually under the appro-
priate methods sections. The cohort
characteristics as a whole are in
Supplementary Table 2.
Biopsies were placed immediately
into ice-cold RPMI 1640 medium and
then washed in Hank’s balanced salt
solution with dithiothreitol 0.01% to
eliminate mucus and debris before
culturing. Biopsies were culture with
either control medium (RPMI 164
supplemented with fetal bovine serum
[5%], L-glutamine [0.01%], penicillin/
streptomycin [0.01%], and gentamycin
[0.0025%]) or medium containing VPA
(5 mM) at 37C in a humidified incu-
bator at 5% CO2 for 24 hours. The
dose of VPA used corresponded to that
used to reduce inflammatory cytokine
production and treat in DSS-exposed
mice.4 VPA was diluted from a stock
50-mM solution dissolved in RPMI
medium.
Following culture, the supernatant
was removed and stored at -80C, and
the biopsies stored either in RNALater
at -80C or FFPE embedded. As a
positive control for treatment (n ¼ 6
pairs), the percentage of H3K27ac
cells was determined as in the immu-
nofluorescence protocol. Difference
between patient-matched biopsies
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treated with either VPA or a vehicle
control (RPMI media) was determined




IBD biopsies stored in RNALater were
homogenized in 700 mL of Qiazol re-
agent and RNA extracted using the
miRNeasy Kit (Qiagen, Hilden, Ger-
many) and RNA quality determined
using a bioanalyzer. RNA was con-
verted to cDNA using the High Capac-
ity RNA-to-cDNA Kit (Applied
Biosystems, Wilmington, DE). The
cDNAs were diluted 1:10 before incu-
bation with commercial Taqman gene
expression probes and Universal
Mastermix (Applied Biosystems) on a
7500 System RealTime PCR cycler
(Applied Biosystems). Resultant cycle
threshold (Ct) values were exported
and normalized to control genes
RPLPO using the 2-DCt method.
All normalized data were log2
transformed before statistical analysis
and normally distributed. IL6 and
HDAC mRNA levels in the DSS mouse
at Day 10 (n ¼ 3) and Day 17 (n ¼ 3)
were compared with baseline at Day
0 (n ¼ 3) using a 2-tailed Student t
test assuming equal variance. Differ-
ences in IL6 mRNA and HDAC mRNA
between inactive (n ¼ 8) and active




Supernatants from cultured IBD
biopsies (n ¼ 21 pairs) were
assessed using a customized 6-plex
Luminex panel according to manu-
facturer’s instructions (EMD Milli-
pore, Billerica, MA). Changes in IL6
were further validated by enzyme-
linked immunosorbent assays
(DY206-05; n ¼ 17 pairs). Data
were not normally distributed and
differences between VPA-treated
biopsies and biopsies cultured
with the vehicle control (RPMI
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Supplementary Figure 1. (A)
A table comparing IL6 and
HDAC mRNA levels between
IBD biopsies with inactive
(n [ 8) and active disease
(n [ 11); with a separate
analysis for patients with CD
(CD inactive and CD active,
n [ 4 and 5, respectively)
and patients with UC (UC
inactive and UC active, n [
4 and 6, respectively). Data
are expressed as log2 fold-
change in active biopsies
relative to the mean level of
expression in inactive bi-
opsies. Differences between
groups were determined using
Student t test, assuming equal
variance, and the P values for
each comparison are given in
the table. (B) The expression
levels for IL6 and HDAC9 are
also graphically represented
(*< .05, **< .01).
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Supplementary Figure 2.
(A) The mRNA levels of
BLC3, which protects against
apoptosis, and (B) CASP9
and (C) CASP3, which pro-
mote apoptosis, were quan-
tified by quantitative
polymerase chain reaction in
paired IBD biopsies treated
with or without 5 mM VPA.
Paired Student t tests
showed a significant
decrease in BCL3 expres-
sion, coupled with an in-
crease in CASP9 mRNA
levels (D–G). There was also
a small increase in the per-
centage of CASP9þ cells
measured using immunoflu-
orescence. This increase was
relatively larger in CD3þ T
cells. However, these differ-
ences did not reach statisti-
cal significance. Significant
changes: ****< .0001. N.S,
not significant.
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Supplementary Table 1.Clinical Characteristics of the FFPE Cohort







1 26 F CD A2L3B2p <5 Yes Steroids
2 37 F CD A?L3B3p 9 Yes None
3 26 F CD A1L1B3 52 Yes Thiopurine
4 38 F CD A?L3B3p 25 Yes Adalimumab and thiopurine
5 19 M CD A1L1B2 7 Yes Adalimumab
9 18 F CD A1L3B3 <5 Yes Steroids
10 23 M CD A2L3B2p 35 Yes Adalimumab and thiopurine
11 36 M CD A1L3B2p Yes Adalimumab and thiopurine
12 64 F CD A3L3B3 53 Yes Adalimumab and steroids
6 35 F UC E3 Yes None
7 50 F UC E3 37 Yes None
8 34 M UC E3 <5 Yes Infliximab
13 47 M UC E1 34 Yes None
14 14 F UC E3 31 Yes Steroids
15 28 M UC E3 9 Yes Biologics and steroids
16 16 M UC E3 10 Yes Immunomodulator and
steroids
17 28 F UC E3 32 Yes Tacrolimus
CD, Crohn’s disease; CRP, C-reactive protein; FFPE, formalin fixed and paraffin embedded; UC, ulcerative colitis.
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Supplementary Table 2.Clinical Characteristics of Patients Used for Biopsy Cultures







cf01 1 44 M CD A1L1L4B2 13 Yes Thiopurine and steroids
cf02 2 20 F CD A1L2L4B1 6 Yes Adalimumab and thiopurine
cf03 3 41 F CD A2L2B1p No None
cf04 4 25 M CD A2L2B1p <5 Yes Thiopurine and steroids
cf05 5 55 M CD A2L3B1P <5 Yes Thiopurine
cf06 6 59 F UC E2 <5 Yes Steroids
cf07 7 59 F UC E1 <5 No None
cf08 8 58 M UC E3 <5 Yes None
cf09 9 68 M UC E3 <5 No None
cf10 10 41 M UC E3 <5 Yes None
cf11 11 35 M UC E2 19 Yes None
cf12 12 37 M CD A1L3B2 <5 Yes None
cf13 13 17 F CD A1L3B2 <5 Yes Thiopurine
cf14 14 40 F UC E3 <5 Yes None
cf15 15 39 F UC E3 <5 No None
cf16 16 21 M UC E3 <5 No Thiopurine and steroids
cf17 17 21 M UC E3 <5 Yes Methotrexate and steroids
cf21 18 50 F UC E2 <5 Yes None
cf23 19 41 M UC E3 <5 Yes Thiopurine
cf24 20 51 F UC E1 <5 Yes None
cf25 21 20 M CD 16 Yes Infliximab
cf26 22 21 M UC E3 <5 No None
cf28 23 27 F CD A2L3B2p <5 No Steroids
cf32 24 59 M CD A3L2B1 <5 No None
cf33 25 40 F UC E3 <5 No None
cf34 26 29 M CD A2L1 <5 Yes Methotrexate
cf36 27 46 F CD A1L3B2 7 Yes None
cf37 28 46 F CD A1L3B2 7 Yes None
cf38 29 43 F CD A2L3B2p <5 Yes Adalimumab and
methotrexate
CD, Crohn’s disease; CRP, C-reactive protein; UC, ulcerative colitis.
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